Imagine trying a dozen different keys to open a door without knowing which one fits. For people with rheumatoid arthritis, finding the right medicine often feels like that trial-and-error process. This work creates a biological 'map' to pick the right drug and dose the first time. It's like switching from a one-size-fits-all outfit to a custom-tailored suit for every patient.
Rheumatoid arthritis treatments are often ineffective because doctors lack the tools to know which drug works for which patient. This leads to expensive trial-and-error prescribing and poor patient adherence.
A set of validated clinical, molecular, and digital biomarkers and collaborative care models to optimize the selection and dosing of DMARDs.
If you are a drug developer dealing with low patient response rates for DMARDs — this project developed biomarker-based selection tools that match patients to the drug with the highest likelihood of benefit. This reduces the waste of ineffective treatments and improves clinical outcome data.
If you are a diagnostic company dealing with a lack of specialized RA monitoring tools — this project developed laboratory measurements for drug levels and biological markers. These tools allow for precise therapeutic drug monitoring to guide treatment adjustments.
If you are a clinic manager dealing with high healthcare costs and poor patient adherence — this project developed collaborative care models and digital biomarkers. These tools increase patient satisfaction and ensure medications are used more effectively.
Based on available project data, specific pricing or cost figures for the biomarkers and care models are not provided.
The project involves 6 industry partners and 4 SMEs, suggesting a focus on scalable clinical application across 10 different countries.
Based on available project data, specific licensing terms are not mentioned, though the consortium includes a mix of universities and industry partners.
The project focuses on creating collaborative care models and using laboratory measurements to guide routine treatment adjustments for DMARDs.
The project period runs from 2022-12-01 to 2027-11-30, indicating it is currently in the clinical study and validation phase.
The consortium is well-balanced for commercialization, featuring a 38% industry ratio with 6 industry partners, including 4 SMEs. The collaboration spans 10 countries and 16 partners, combining the academic rigor of 7 universities with the practical application capabilities of private companies, which reduces the gap between lab research and market entry.
Contact the Medizinische Universitaet Wien
Contact us to explore licensing opportunities for RA biomarkers.
